Kings Path Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Kings Path Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.24M	Hold	3,960	–	–	0.33%	36
2026 Q2	$1.25M	Hold	3,960	–	–	0.33%	35
2026 Q1	$791K	Hold	3,960	–	–	0.27%	41
2025 Q4	$749K	Hold	3,960	–	–	0.26%	41
2025 Q3	$701K	Sell	3,960 -1,105	-22%	-$164K	0.26%	40
2025 Q2	$576K	Hold	5,065	–	–	0.23%	49
2025 Q1	$533K	Sell	5,065 -3,195	-39%	-$361K	0.26%	51
2024 Q4	$885K	Hold	8,260	–	–	0.38%	69
2024 Q3	$827K	Buy	8,260 +1,380	+20%	+$139K	0.35%	76
2024 Q2	$580K	Buy	+6,880	New	+$547K	0.27%	90

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Kings Path Partners's LGND Position: Q3 2026 in Review

Kings Path Partners held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 3,960 shares worth $1.24M. The position accounts for 0.33% of the portfolio, ranked #36.

Kings Path Partners first reported a position in LGND in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.25M in Q2 2026. 97 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Kings Path Partners held 3,960 shares of Ligand Pharmaceuticals worth $1.24M as of Q3 2026.
Kings Path Partners left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
Ligand Pharmaceuticals made up 0.33% of Kings Path Partners's portfolio in Q3 2026, its #36 holding.
Kings Path Partners first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
Kings Path Partners's Ligand Pharmaceuticals position peaked at $1.25M in Q2 2026.
97 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Kings Path Partners's 13F filing for Q3 2026, filed 21 Oct 2026.